The grant, plainly. On October 22, 2024, NanoVation Therapeutics was issued US12121591B2, covering sulfur-containing ionizable lipids for nucleic-acid delivery. The CPC tags — A61K 47/6929 (conjugate delivery), A61K 9/5123 (lipid particles), plus the C07C 323 sulfur-chemistry series — describe a novel lipid class, the active ingredient that drives delivery efficiency.
Why a financing desk reads lipid IP: the ionizable lipid is the heart of an LNP, and a differentiated lipid class is the kind of platform asset a delivery-focused company is built on. When such a company raises, the lipid IP is what the capital is funding toward — and what a partner would license.
The cautionary read: a strong lipid patent supports the equity story but does not extend runway. Cash divided by burn sets the clock, and a development-stage delivery company typically needs multiple financings to mature its platform. The holder's question is whether each raise buys enough quarters to reach a partnership or clinical inflection before the next dilution.
What the grant does not show: cash, burn, share count, or dilution history. Those are in the filings. The grant establishes the differentiated lipid asset and its scope.
The takeaway: treat a novel ionizable-lipid grant as the platform collateral behind a delivery-company raise, then do the dilution and runway math from the filings. NanoVation's October 2024 lipid grant is a dated example of the delivery IP such a financing rests on.